Anti-HIV agent conocurvone
Executive Summary
NIH announces in the Dec. 10 Federal Register that it is contemplating granting an exclusive worldwide license to a U.S. use and composition patent for conocurvone and other antiviral naphthoquinone compounds in inhibiting the growth or replication of viruses, particularly HIV-1 or HIV-2. The licensee would be the Australian Medical Research and Development Consortium (AMRAD) of Kew, Victoria, Australia. NIH announced in August that conocurvone was available for exclusive license ("The Pink Sheet" Sept. 13, T&G-10). The compounds are derived from the smokebush of the genus Conospermum found in western Australia.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth